A Double-Blind Controlled Trial of Betamethasone Dipropionate 0·05% (Diproderm®) in Comparison with Fluocinolone Acetonide 0·025% (Synalar®) in Psoriasis and other Steroid-Responsive Dermatoses

Abstract

In a double-blind randomized study, sixty-two patients suffering from psoriasis or eczema were treated, twice daily for three weeks, either with 0.05% betamethasone 17, 21-dipropionate cream or with 0.025% fluocinolone acetonide cream. The results showed that both topical corticosteroid preparations were effective, well tolerated and cosmetically acceptable. Fifty-seven per cent of the patients treated with betamethasone dipropionate were rated as being 'much better' in the overall assessment of response at the end of the trial period compared to only 25% of those in the fluocinolone acetonide group.

Diprosone* (betamethasone dipropionate) cream 0.05%. A Review and Interim Report of a Comparative Multi‐centre Study Versus betamethasone valerate 0.1%

“…Diprosone has been shown to have a high degree of efficacy and tolerance which has been previously well demonstrated in comparative clinical studies 1,2,3,4,5 …”

“…Sweden which operated similar potency classifications, Diprosone has been classified in the same group as betamethasone valerate. Its high degree of efficacy and tolerance has been well demonstrated in previous clinical studies showing superiority over betamethasone valerate; 1 fluocinolone acetonide, 2,3,4 and hydrocortisone butyrate 5…”